Trial endpoints
ADVERSE EVENTS, SECONDARY, RECURRENCE
The primary endpoint was the proportion of patients converting from AF to sinus rhythm within 90 min from the start of the infusion and who subsequently had no AF recurrence within 1 min of conversion. Key secondary efficacy endpoints included time to conversion from AF, the proportion of patients with relapse of AF within 5 min after pharmacological (AP30663) or direct current cardioversion and the proportion of patients in sinus rhythm at 3 and 24 h after the start of the infusion. Key secondary safety endpoints included adverse events and change in QT interval corrected using the Fridericia formula (QTcF). Pharmacokinetics were also assessed as a secondary endpoint.Exploratory endpoints addressing the potential for treatment effect interactions with baseline variables and pharmacokinetic parameters were specified in the protocol; however, due to the limited sample size, these analyses were severely underpowered and are not reported in this article.